US medical experts are reportedly concerned that a neurological side effect picked up in AstraZeneca’s closely-watched COVID-19 vaccine trial could compromise the whole project, as the FDA
Gilead has made another big oncology acquisition, paying $21 billion for US biotech Immunomedics and its potential cancer blockbuster Trodelvy, days before survival data is due to be reveal
UK cost-effectiveness watchdog NICE has changed its stance on AstraZeneca’s Tagrisso as a first-line therapy for non-small cell lung cancer (NSCLC) after an improved “commercial arrangement
AstraZeneca’s pause of its COVID-19 vaccine trial is a “wake-up call” demonstrating the challenges of the development process, according to the World Health Organization’s chief scientist.<
AstraZeneca’s Fasenra (benralizumab) injected drug cuts the size of nasal polyps and nasal blockage in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.